Back
ESC Premium Access

Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy? – discussion.

Session: Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy?
Topic: Peripheral Vascular and Cerebrovascular Disease
Speaker: Professor I. Baumgartner (Bern, CH)
Event: ESC Congress 2021 - The Digital Experience

Presentation

0

About the speaker

Professor Iris Baumgartner

University Hospital, Bern (Switzerland)
3 presentations
0 follower

2 more presentations in this session

After peripheral endovascular therapy, DAPT remains the preferred option over dual-pathway antithrombotic therapy: pro.

Speaker: Professor C. Heiss (Guildford, GB)

Access
Slides
Video
0
Thumbnail

After peripheral endovascular therapy, DAPT remains the preferred option over dual-pathway antithrombotic therapy: con.

Speaker: Professor M. Brodmann (Graz, AT)

Access
Slides
Video
0
Thumbnail

Access the full session

Great Debate: antithrombotic therapeutic dilemmas in PAD – dual antiplatelet or dual-pathway antithrombotic therapy?

Speakers: Professor I. Baumgartner, Professor C. Heiss, Professor M. Brodmann
Access
Video
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Choosing wisely: ablation or medication for rhythm control in atrial fibrillation – discussion.

27 August 2021

ESC Premium Access

Ablation or amiodarone for HFrEF patients with atrial fibrillation?

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by

logo Novo Nordisk